Loading...

ImpediMed

ASX:IPD
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IPD
ASX
A$84M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

ImpediMed Limited, together with its subsidiaries, develops, manufactures, and sells bioimpedance instruments, consumables, and software in Australia, North America, and internationally. The last earnings update was 60 days ago. More info.


Add to Portfolio Compare Print
IPD Share Price and Events
7 Day Returns
7.3%
ASX:IPD
4.1%
AU Medical Equipment
-0%
AU Market
1 Year Returns
-67.2%
ASX:IPD
-3.3%
AU Medical Equipment
4.9%
AU Market
IPD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ImpediMed (IPD) 7.3% 2.3% 10% -67.2% -76.5% 4.8%
AU Medical Equipment 4.1% 0.7% 0.8% -3.3% 38.7% 103.7%
AU Market -0% 1.4% 6.5% 4.9% 18.2% 4.8%
1 Year Return vs Industry and Market
  • IPD underperformed the Medical Equipment industry which returned -3.3% over the past year.
  • IPD underperformed the Market in Australia which returned 4.9% over the past year.
Price Volatility
IPD
Industry
5yr Volatility vs Market

IPD Value

 Is ImpediMed undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for ImpediMed. This is due to cash flow or dividend data being unavailable. The share price is A$0.22.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ImpediMed's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ImpediMed's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:IPD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.07
ASX:IPD Share Price ** ASX (2019-04-18) in AUD A$0.22
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 33.38x
Australia Market PE Ratio Median Figure of 544 Publicly-Listed Companies 16.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ImpediMed.

ASX:IPD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:IPD Share Price ÷ EPS (both in AUD)

= 0.22 ÷ -0.07

-3.35x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ImpediMed is loss making, we can't compare its value to the AU Medical Equipment industry average.
  • ImpediMed is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does ImpediMed's expected growth come at a high price?
Raw Data
ASX:IPD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.35x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
64.6%per year
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.62x
Australia Market PEG Ratio Median Figure of 360 Publicly-Listed Companies 1.35x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ImpediMed, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ImpediMed's assets?
Raw Data
ASX:IPD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.07
ASX:IPD Share Price * ASX (2019-04-18) in AUD A$0.22
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.72x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.67x
ASX:IPD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:IPD Share Price ÷ Book Value per Share (both in AUD)

= 0.22 ÷ 0.07

3.12x

* Primary Listing of ImpediMed.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ImpediMed is overvalued based on assets compared to the AU Medical Equipment industry average.
X
Value checks
We assess ImpediMed's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. ImpediMed has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

IPD Future Performance

 How is ImpediMed expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
64.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ImpediMed expected to grow at an attractive rate?
  • ImpediMed's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
  • ImpediMed's earnings growth is expected to exceed the Australia market average.
  • ImpediMed's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:IPD Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:IPD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 64.6%
ASX:IPD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 57.4%
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.2%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:IPD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:IPD Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-06-30 130 105 68 1
2022-06-30 72 48 22 1
2021-06-30 38 2 -8 1
2020-06-30 19 -15 -19 1
2019-06-30 9 -19 -24 1
ASX:IPD Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 5 -21 -25
2018-09-30 5 -22 -26
2018-06-30 5 -23 -27
2018-03-31 4 -25 -28
2017-12-31 4 -26 -28
2017-09-30 5 -26 -28
2017-06-30 6 -26 -28
2017-03-31 6 -25 -28
2016-12-31 6 -25 -29
2016-09-30 6 -24 -27
2016-06-30 6 -22 -26
2016-03-31 6 -19 -23

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ImpediMed's earnings are expected to grow significantly at over 20% yearly.
  • ImpediMed's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:IPD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from ImpediMed Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:IPD Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-06-30 0.18 0.18 0.18 1.00
2022-06-30 0.06 0.06 0.06 1.00
2021-06-30 -0.02 0.00 -0.03 3.00
2020-06-30 -0.05 -0.04 -0.05 3.00
2019-06-30 -0.07 -0.06 -0.07 3.00
ASX:IPD Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.07
2018-09-30 -0.07
2018-06-30 -0.07
2018-03-31 -0.07
2017-12-31 -0.08
2017-09-30 -0.07
2017-06-30 -0.07
2017-03-31 -0.08
2016-12-31 -0.08
2016-09-30 -0.08
2016-06-30 -0.08
2016-03-31 -0.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • ImpediMed is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess ImpediMed's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ImpediMed has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

IPD Past Performance

  How has ImpediMed performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ImpediMed's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ImpediMed does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ImpediMed's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ImpediMed's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
ImpediMed's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ImpediMed Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:IPD Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 5.08 -24.89 28.47 2.78
2018-09-30 4.94 -26.03 29.44 2.88
2018-06-30 4.80 -27.17 30.42 2.98
2018-03-31 4.32 -27.70 30.18 3.39
2017-12-31 4.41 -28.21 30.27 3.80
2017-09-30 5.09 -27.89 29.87 4.57
2017-06-30 5.77 -27.57 29.47 5.34
2017-03-31 5.86 -28.06 30.21 5.60
2016-12-31 5.95 -28.56 30.95 5.87
2016-09-30 5.87 -27.27 29.72 4.95
2016-06-30 5.79 -25.98 28.48 4.04
2016-03-31 5.63 -22.94 25.16 3.09
2015-12-31 5.47 -19.89 21.84 2.13
2015-09-30 5.16 -17.34 19.66 1.58
2015-06-30 4.84 -14.80 17.48 1.04
2015-03-31 4.42 -12.63 15.30 0.75
2014-12-31 3.99 -10.47 13.11 0.47
2014-09-30 3.76 -9.20 11.58 0.44
2014-06-30 3.52 -7.94 10.05 0.40
2014-03-31 3.30 -7.41 9.71 0.35
2013-12-31 3.08 -6.89 9.37 0.29
2013-09-30 2.91 -7.67 9.81 0.42
2013-06-30 2.73 -8.46 10.26 0.55
2013-03-31 2.77 -10.02 10.65 1.32
2012-12-31 2.81 -11.57 11.05 2.09
2012-09-30 2.88 -11.96 11.17 2.44
2012-06-30 2.95 -12.34 11.29 2.78

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ImpediMed has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ImpediMed has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ImpediMed improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ImpediMed's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ImpediMed has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

IPD Health

 How is ImpediMed's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ImpediMed's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ImpediMed is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ImpediMed's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ImpediMed's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • ImpediMed has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ImpediMed Company Filings, last reported 3 months ago.

ASX:IPD Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 26.68 0.00 22.64
2018-09-30 26.68 0.00 22.64
2018-06-30 36.00 0.00 31.35
2018-03-31 36.00 0.00 31.35
2017-12-31 45.22 0.00 42.41
2017-09-30 45.22 0.00 42.41
2017-06-30 58.80 0.00 54.88
2017-03-31 58.80 0.00 54.88
2016-12-31 74.99 0.00 73.24
2016-09-30 74.99 0.00 73.24
2016-06-30 85.25 0.00 82.25
2016-03-31 85.25 0.00 82.25
2015-12-31 26.65 0.00 25.15
2015-09-30 26.65 0.00 25.15
2015-06-30 34.84 0.00 32.58
2015-03-31 34.84 0.00 32.58
2014-12-31 40.24 0.00 38.24
2014-09-30 40.24 0.00 38.24
2014-06-30 13.53 0.00 10.81
2014-03-31 13.53 0.00 10.81
2013-12-31 7.39 0.00 4.54
2013-09-30 7.39 0.00 4.54
2013-06-30 10.59 0.00 7.32
2013-03-31 10.59 0.00 7.32
2012-12-31 12.75 0.00 9.65
2012-09-30 12.75 0.00 9.65
2012-06-30 17.31 0.00 14.51
  • ImpediMed has no debt.
  • ImpediMed has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ImpediMed has less than a year of cash runway based on current free cash flow.
  • ImpediMed has less than a year of cash runway if free cash flow continues to grow at historical rates of 7.9% each year.
X
Financial health checks
We assess ImpediMed's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ImpediMed has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

IPD Dividends

 What is ImpediMed's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ImpediMed dividends. Estimated to be 0% next year.
If you bought A$2,000 of ImpediMed shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ImpediMed's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ImpediMed's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:IPD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:IPD Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2023-06-30
2022-06-30 0.00 1.00
2021-06-30 0.00 2.00
2020-06-30 0.00 2.00
2019-06-30 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ImpediMed has not reported any payouts.
  • Unable to verify if ImpediMed's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ImpediMed's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ImpediMed has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of ImpediMed's dividends in 3 years as they are not expected to pay a notable one for Australia.
X
Income/ dividend checks
We assess ImpediMed's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ImpediMed afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ImpediMed has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

IPD Management

 What is the CEO of ImpediMed's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rick Carreon
COMPENSATION A$2,395,774
TENURE AS CEO 6.8 years
CEO Bio

Mr. Richard Carreon, also known as Rick, has been the Managing Director of ImpediMed Limited since May 9, 2015 and as its Chief Executive Officer and President since July 10, 2012. Mr. Carreon is a seasoned executive in the medical devices field in North America, having spent 11 years in senior (Vice President) roles with Medtronic Inc., a global provider of medical technologies and devices. During that time, Mr. Carreon has been an Executive Director of ImpediMed Limited since May 09, 2015. He has been involved in successfully bringing new technologies to market and expanding existing product penetration. His strong sales background is coupled with leadership in cost management and synergistic leverage across business units.

CEO Compensation
  • Rick's compensation has increased whilst company is loss making.
  • Rick's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the ImpediMed management team in years:

4.4
Average Tenure
  • The tenure for the ImpediMed management team is about average.
Management Team

Rick Carreon

TITLE
MD, CEO
COMPENSATION
A$2M
TENURE
6.8 yrs

Morten Vigeland

TITLE
Chief Financial Officer
COMPENSATION
A$1M
TENURE
5.6 yrs

Dave Adams

TITLE
Senior Vice President of Ventures
COMPENSATION
A$909K
TENURE
2.7 yrs

Dennis Schlaht

TITLE
Senior Vice President of R&D and Technology
COMPENSATION
A$859K

Cath Kingsford

TITLE
Senior Vice President of Medical Affairs
COMPENSATION
A$856K

Shashi Tripathi

TITLE
Chief Technology Officer
TENURE
1.3 yrs

Frank Vicini

TITLE
Chief Medical Officer
TENURE
4.6 yrs

Leanne Ralph

TITLE
Company Secretary
TENURE
4.3 yrs
Board of Directors Tenure

Average tenure and age of the ImpediMed board of directors in years:

2.1
Average Tenure
59
Average Age
  • The average tenure for the ImpediMed board of directors is less than 3 years, this suggests a new board.
Board of Directors

Scott Ward

TITLE
Non-Executive Chairman
COMPENSATION
A$129K
AGE
58
TENURE
1.4 yrs

Rick Carreon

TITLE
MD, CEO
COMPENSATION
A$2M
TENURE
3.9 yrs

Don Williams

TITLE
Non-Executive Director
COMPENSATION
A$98K
AGE
59
TENURE
2.1 yrs

Judith Downes

TITLE
Non-Executive Director
COMPENSATION
A$82K
AGE
64
TENURE
2 yrs

Gary Goetzke

TITLE
Non-Executive Director
COMPENSATION
A$87K
TENURE
2.7 yrs

Amit Patel

TITLE
Non-Executive Director
COMPENSATION
A$87K
TENURE
2.1 yrs

Bob Graham

TITLE
Non-Executive Director
COMPENSATION
A$46K
TENURE
1.4 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by ImpediMed insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
24. Mar 19 Buy Gary Goetzke Individual 20. Mar 19 20. Mar 19 242,000 A$0.23 A$54,450
24. Mar 19 Buy Amit Patel Individual 20. Mar 19 20. Mar 19 88,000 A$0.23 A$19,800
22. Mar 19 Sell Macquarie Investment Management Australia Limited Company 05. Sep 18 24. Sep 18 -253,890 A$0.49 A$0
22. Mar 19 Sell Macquarie Group, Ltd., Banking & Securities Investments Company 28. Aug 18 20. Sep 18 -2,975,219 A$0.51 A$0
22. Mar 19 Buy Macquarie Group, Ltd., Banking & Securities Investments Company 21. Sep 18 21. Sep 18 59,993 A$0.46 A$27,597
22. Mar 19 Sell Macquarie Investment Management Limited Company 13. Aug 18 18. Mar 19 -3,553,517 A$0.50 A$0
22. Mar 19 Buy Macquarie Investment Management Limited Company 09. Aug 18 11. Mar 19 5,444,050 A$0.52 A$0
19. Mar 19 Sell FIL Limited Company 05. Feb 19 15. Mar 19 -3,888,315 A$0.25 A$-899,079
12. Mar 19 Buy Donald Williams Individual 13. Mar 19 13. Mar 19 10,000 A$0.24 A$2,350
11. Mar 19 Buy Scott Ward Individual 11. Mar 19 11. Mar 19 25,000 A$0.24 A$5,883
08. Mar 19 Buy Donald Williams Individual 08. Mar 19 08. Mar 19 10,000 A$0.24 A$2,400
06. Mar 19 Buy Donald Williams Individual 06. Mar 19 06. Mar 19 80,000 A$0.25 A$20,000
11. Feb 19 Sell Starfish Ventures Pty Ltd Company 28. Aug 18 07. Feb 19 -3,677,775 A$0.54 A$-977,253
06. Feb 19 Sell FIL Limited Company 03. Jan 19 04. Feb 19 -3,875,449 A$0.24 A$-928,944
05. Feb 19 Buy UniSuper Limited Company 30. Jan 19 01. Feb 19 843,555 A$0.24 A$197,080
06. Jan 19 Sell FIL Limited Company 30. Jan 18 02. Jan 19 -4,347,426 A$0.84 A$0
06. Jan 19 Buy FIL Limited Company 15. Nov 17 25. Oct 18 1,909,186 A$0.93 A$0
30. Aug 18 Sell Morgan Stanley, Investment Banking and Brokerage Investments Company 27. Aug 18 28. Aug 18 -232,051 A$0.48 A$-110,565
30. Aug 18 Buy Morgan Stanley, Investment Banking and Brokerage Investments Company 27. Aug 18 28. Aug 18 17,394 A$0.49 A$8,549
28. Aug 18 Buy Morgan Stanley, Investment Banking and Brokerage Investments Company 15. Aug 18 24. Aug 18 85,488 A$0.32 A$27,354
13. Aug 18 Sell Macquarie Investment Management Limited Company 02. Jul 18 30. Jul 18 -56,895 A$0.46 A$0
13. Aug 18 Buy Macquarie Investment Management Limited Company 29. Jun 18 08. Aug 18 3,895,815 A$0.46 A$0
14. Aug 18 Sell Morgan Stanley, Investment Banking and Brokerage Investments Company 08. Aug 18 10. Aug 18 -186,325 A$0.36 A$-67,549
14. Aug 18 Buy Morgan Stanley, Investment Banking and Brokerage Investments Company 08. Aug 18 10. Aug 18 518,947 A$0.37 A$184,808
09. Aug 18 Buy Morgan Stanley, Investment Banking and Brokerage Investments Company 26. Jul 18 07. Aug 18 246,547 A$0.41 A$93,853
27. Jul 18 Sell Morgan Stanley, Investment Banking and Brokerage Investments Company 25. Jul 18 25. Jul 18 -41,000 A$0.43 A$-17,711
27. Jul 18 Buy Morgan Stanley, Investment Banking and Brokerage Investments Company 25. Jul 18 25. Jul 18 24,905 A$0.43 A$10,679
26. Jul 18 Buy Morgan Stanley, Investment Banking and Brokerage Investments Company 26. Mar 18 24. Jul 18 2,538,088 A$0.57 A$1,440,528
03. Jul 18 Sell Macquarie Investment Management Australia Limited Company 28. Jun 18 28. Jun 18 -6,763 A$0.40 A$-2,705
03. Jul 18 Buy Macquarie Investment Management Australia Limited Company 27. Jun 18 28. Jun 18 81,024 A$0.42 A$32,709
29. Jun 18 Buy Macquarie Investment Management Australia Limited Company 26. Jun 18 26. Jun 18 6,434 A$0.42 A$2,702
29. Jun 18 Sell Macquarie Group, Ltd., Banking & Securities Investments Company 26. Jun 18 26. Jun 18 -2,539,423 A$0.44 A$-1,117,346
28. Jun 18 Sell Macquarie Investment Management Australia Limited Company 05. Mar 18 18. Jun 18 -25,910 A$0.78 A$0
28. Jun 18 Buy Macquarie Investment Management Australia Limited Company 26. Feb 18 25. Jun 18 6,709,587 A$0.78 A$0
29. May 18 Buy Gary Goetzke Individual 22. May 18 22. May 18 14,100 A$0.55 A$7,685
X
Management checks
We assess ImpediMed's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ImpediMed has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

IPD News

Simply Wall St News

Can We See Significant Institutional Ownership On The ImpediMed Limited (ASX:IPD) Share Register?

The big shareholder groups in ImpediMed Limited (ASX:IPD) have power over the company. … Generally speaking, as a company grows, institutions will increase their ownership. … Our analysis of the ownership of the company, below, shows that.

Simply Wall St -

ImpediMed Limited (ASX:IPD): When Will It Breakeven?

The AU$87m market-cap posted a loss in its most recent financial year of -AU$27.2m and a latest trailing-twelve-month loss of -AU$24.9m shrinking the gap between loss and breakeven. … I’ve put together a brief outline of industry analyst expectations for IPD, its year of breakeven and its implied growth rate … According to the 3 industry analysts covering IPD, the consensus is breakeven is near.

Simply Wall St -

Is ImpediMed Limited's (ASX:IPD) CEO Pay Justified?

Rick Carreon became the CEO of ImpediMed Limited (ASX:IPD) in 2012. … First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Rick Carreon's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Will ImpediMed Limited's (ASX:IPD) Earnings Grow In The Next Couple Of Years?

ImpediMed Limited's (ASX:IPD) most recent earnings update in June 2018 … company earnings became less negative compared to the previous year's level

Simply Wall St -

Why ImpediMed Limited’s (ASX:IPD) Cash Is A Factor You Need To Consider

Two important questions to ask before you buy ImpediMed Limited (ASX:IPD) is, how it makes money and how it spends its cash. … I’ve analysed below, the health and outlook of ImpediMed’s cash flow, which will help you understand the stock from a cash standpoint. … The two ways to assess whether ImpediMed’s FCF is sufficient, is to compare the FCF yield to the market index yield, as well as determine whether the top-line operating cash flows will continue to grow

Simply Wall St -

How Much Of ImpediMed Limited (ASX:IPD) Do Institutions Own?

Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … Companies that used to be publicly owned tend to have lower insider ownership. … institutions own shares in the company.

Simply Wall St -

Should You Be Happy With ImpediMed Limited's (ASX:IPD) Performance Lately?

When ImpediMed Limited's (ASX:IPD) announced its latest earnings (30 June 2018), I wanted to understand how these figures stacked up against its past performance. … The two benchmarks I used were ImpediMed's average earnings over the past couple of years, and its industry performance. … IPD is loss-making, with the most recent trailing twelve-month earnings of -AU$27.2m (from 30 June 2018), which compared to last year has become.

Simply Wall St -

Is ImpediMed Limited (ASX:IPD) A Financially Sound Company?

ImpediMed Limited (ASX:IPD), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … Is financial flexibility worth the lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

Is ImpediMed Limited's (ASX:IPD) CEO Overpaid Relative To Its Peers?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Rick Carreon's Compensation Compare With Similar Sized Companies. … As you can see, Rick Carreon is paid more than the median CEO pay at companies of a similar size, in the same market

Simply Wall St -

Why ImpediMed Limited's (ASX:IPD) Ownership Structure Is Important

In this article, I'm going to take a look at ImpediMed Limited’s (ASX:IPD) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … A company's ownership structure is often linked to its share performance in both the long- and short-term. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment.

Simply Wall St -

IPD Company Info

Description

ImpediMed Limited, together with its subsidiaries, develops, manufactures, and sells bioimpedance instruments, consumables, and software in Australia, North America, and internationally. The company operates through Medical and Test & Measurement segments. It offers SOZO, a next generation bioimpedance spectroscopy digital health platform; and L-Dex U400, a technology that utilizes the characteristics of frequency dependent current flow to quantify changes in extracellular fluid in the patient’s limb. The company also provides SFB7, a tetra polar bioimpedance spectroscopy device that scans various frequencies for the estimation of body composition in healthy individuals; and ImpediVET, a bioimpedance spectroscopy technology for use in veterinary applications. In addition, the company supplies power precision testing and measuring equipment. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.

Details
Name: ImpediMed Limited
IPD
Exchange: ASX
Founded: 1999
A$83,551,259
379,778,454
Website: http://www.impedimed.com
Address: ImpediMed Limited
50 Parker Court,
Unit 1,
Pinkenba,
Queensland, 4008,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX IPD Ordinary Shares Australian Securities Exchange AU AUD 24. Oct 2007
OTCPK IPDQ.F Ordinary Shares Pink Sheets LLC US USD 24. Oct 2007
DB 39I Ordinary Shares Deutsche Boerse AG DE EUR 24. Oct 2007
CHIA IPD Ordinary Shares Chi-X Australia AU AUD 24. Oct 2007
Number of employees
Current staff
Staff numbers
68
ImpediMed employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 10:34
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/03
Last earnings filing: 2019/02/20
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.